Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIVOT-02: Bempegaldesleukin + Nivolumab in Advanced Solid Tumors
NCT02983045Phase 2Completed
- Sponsor
- Nektar Therapeutics
- Start
- Dec 2016
- Primary completion
- Apr 2022
- Modality
- Cytokines & Interferons
- Countries
- 8
01
Overview
A Phase 2 trial of bempegaldesleukin in melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), sponsored by Nektar Therapeutics. Started Dec 2016; status: completed.
02
Drugs
bempegaldesleukin
03
Conditions
melanomarenal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02983045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02983045.